Loading
A phase 3 trial of fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Seoul National University Hospital, now recruiting.
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) is a phase 3, randomised interventional study registered as NCT05529940 by Seoul National University Hospital, with a registry enrolment figure of 609 participants, started 2023-04-01 and due to reach its primary completion in 2024-12. Interventions recorded: Folfirinox. Conditions listed: Resectable Pancreatic Cancer; Neoadjuvant Chemotherapy; Effects of Chemotherapy. Primary outcome: 2-year survival rate. Pancreatic eligibility wording from the registry: "Pancreatic ductal adenocarcinoma diagnosed by histological examination (histologic or cytopathological) D". Sites: South Korea. No results are recorded here; the registry entry is the source.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.